MHRA approves Seagen’s Tukysa for HER2-positive breast cancer
Drug approved in a combination regimen for advanced breast cancer patients
Read More
Tag: HER2-positive
New Herceptin combo could keep breast cancers at bay
Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin is effective at treating women with breast cancer who have no other treatment options.
Read More
AZ announces Phase I DS-8201 results
Approximately one in five breast and gastric cancers are HER2-positive.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
